Literature DB >> 22592978

Effects of hepatocyte growth factor overexpressed bone marrow-derived mesenchymal stem cells on prevention from left ventricular remodelling and functional improvement in infarcted rat hearts.

Shenxu Wang1, Xing Qin, Dongdong Sun, Yunfang Wang, Xiaoyan Xie, Weiwei Fan, Yabin Wang, Dong Liang, Xuetao Pei, Feng Cao.   

Abstract

Bone marrow-derived mesenchymal stem cells (BM-MSCs ) transplantation has been reported to be a promising therapy for myocardial infarction (MI). However, low survival rate of BM-MSCs in infarcted heart is one of the major limitations for the perspective clinical application. In this study, we aimed to investigate the effect of hepatocyte growth factor (HGF) on left ventricular function improvement of HGF gene-modified BM-MSCs (HGF-MSCs) after its delivery into the infarcted rat hearts. BM-MSCs were isolated with fibroblast-like morphology and expressed CD44+CD29+CD90+/CD34-CD45-CD31-CD11a. After 5-azacytidine induction in vitro, 20%-30% of the cells were positively stained for desmin, cardiac-specific cardiac troponin I and connexin-43. Histological staining revealed that 2 weeks after MI is an optimal time point with decreased neutrophil infiltration and increased vascular number. Minimal infarct size and best haemodynamic analysis were also observed after cell injection at 2 weeks compared with that of 1 h, 1 week or 4 weeks. Echocardiogram confirmed that transplantation with HGF-MSCs significantly improved left ventricular function compared with other groups in rat MI models. MSCs and HGF-MSCslabelled with DAPI were detected 4 weeks after MI in the infarcted area. Decreased infarcted scar area and increased angiogenesis formation could be found in HGF-MSCs group than in other groups as demonstrated by hematoxylin and eosin (H&E) staining and factor VIII staining. These results indicate that HGF-MSCs transplantation could enhance the contractile function and attenuate left ventricular remodelling efficiently in rats with MI.
Copyright © 2012 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22592978     DOI: 10.1002/cbf.2836

Source DB:  PubMed          Journal:  Cell Biochem Funct        ISSN: 0263-6484            Impact factor:   3.685


  10 in total

1.  Molecular imaging of stem cells for the treatment of acute myocardial infarction.

Authors:  Xiao Li; Yi-Ning Wang; Zheng-Yu Jin
Journal:  Int J Clin Exp Med       Date:  2015-06-15

2.  Influence of caspase-3 silencing on the proliferation and apoptosis of rat bone marrow mesenchymal stem cells under hypoxia.

Authors:  Ping Hua; Jialiang Liu; Jun Tao; Jianyang Liu; Songran Yang
Journal:  Int J Clin Exp Med       Date:  2015-02-15

Review 3.  Can the outcomes of mesenchymal stem cell-based therapy for myocardial infarction be improved? Providing weapons and armour to cells.

Authors:  Andrey A Karpov; Daria V Udalova; Michael G Pliss; Michael M Galagudza
Journal:  Cell Prolif       Date:  2016-11-23       Impact factor: 6.831

4.  Lipocalin-2-mediated upregulation of various antioxidants and growth factors protects bone marrow-derived mesenchymal stem cells against unfavorable microenvironments.

Authors:  Raheleh Halabian; Hossein Abdul Tehrani; Ali Jahanian-Najafabadi; Mehryar Habibi Roudkenar
Journal:  Cell Stress Chaperones       Date:  2013-04-26       Impact factor: 3.667

5.  Hepatocyte growth factor gene-modified bone marrow-derived mesenchymal stem cells transplantation promotes angiogenesis in a rat model of hindlimb ischemia.

Authors:  Guan-Hua Su; Yu-Fei Sun; Yong-Xin Lu; Xin-Xin Shuai; Yu-Hua Liao; Qi-Yun Liu; Jun Han; Ping Luo
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2013-08-01

6.  Association between Hepatocyte Growth Factor (HGF) Gene Polymorphisms and Serum HGF Levels in Patients with Rheumatoid Arthritis.

Authors:  Fatih Kara; Abdulkadir Yildirim; Musa Gumusdere; Saliha Karatay; Kadir Yildirim; Ebubekir Bakan
Journal:  Eurasian J Med       Date:  2014-08-26

Review 7.  Recent advances in the therapeutic efficacy of hepatocyte growth factor gene-modified mesenchymal stem cells in multiple disease settings.

Authors:  Hong-Fang Meng; Jide Jin; Hua Wang; Li-Sheng Wang; Chu-Tse Wu
Journal:  J Cell Mol Med       Date:  2022-08-03       Impact factor: 5.295

Review 8.  Growth Factor Gene-Modified Mesenchymal Stem Cells in Tissue Regeneration.

Authors:  Wen-Bo Nie; Dan Zhang; Li-Sheng Wang
Journal:  Drug Des Devel Ther       Date:  2020-03-26       Impact factor: 4.162

9.  Combined administration of mesenchymal stem cells overexpressing IGF-1 and HGF enhances neovascularization but moderately improves cardiac regeneration in a porcine model.

Authors:  Guadalupe Gómez-Mauricio; Isabel Moscoso; María-Fernanda Martín-Cancho; Verónica Crisóstomo; Cristina Prat-Vidal; Claudia Báez-Díaz; Francisco M Sánchez-Margallo; Antonio Bernad
Journal:  Stem Cell Res Ther       Date:  2016-07-16       Impact factor: 6.832

10.  Treatment of Myocardial Infarction with Gene-modified Mesenchymal Stem Cells in a Small Molecular Hydrogel.

Authors:  Zhiye Wu; Guoqin Chen; Jianwu Zhang; Yongquan Hua; Jinliang Li; Bei Liu; Anqing Huang; Hekai Li; Minsheng Chen; Caiwen Ou
Journal:  Sci Rep       Date:  2017-11-20       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.